Cue Historical Income Statement
| CUE Stock | USD 1.09 0.07 6.86% |
Historical analysis of Cue Biopharma income statement accounts such as Interest Expense of 1.2 M, Selling General Administrative of 11.7 M or Total Revenue of 3.6 M can show how well Cue Biopharma performed in making a profits. Evaluating Cue Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cue Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cue Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cue Biopharma is a good buy for the upcoming year.
Cue |
About Cue Income Statement Analysis
Cue Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cue Biopharma shareholders. The income statement also shows Cue investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cue Biopharma Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts Cue Biopharma generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Cue Biopharma minus its cost of goods sold. It is profit before Cue Biopharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Cue Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.At present, Cue Biopharma's Cost Of Revenue is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 35.9 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Income | 928.2K | 2.7M | 3.1M | 3.2M | Net Interest Income | 214.4K | 1.4M | 1.6M | 1.7M |
Cue Biopharma income statement Correlations
Click cells to compare fundamentals
Cue Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cue Biopharma income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 1.1M | (1.8M) | 1.8M | 3.4M | 4.0M | 4.1M | |
| Interest Expense | 463.9K | 1.7M | 713.8K | 1.2M | 1.4M | 1.2M | |
| Selling General Administrative | 14.7M | 17.3M | 16.2M | 16.7M | 19.2M | 11.7M | |
| Total Revenue | 3.2M | 14.9M | 1.2M | 5.5M | 6.3M | 3.6M | |
| Gross Profit | (30.4M) | 14.9M | (560.8K) | (32.6M) | (29.3M) | (27.9M) | |
| Other Operating Expenses | 48.2M | 58.7M | 54.7M | 57.6M | 66.3M | 40.6M | |
| Operating Income | (45.0M) | (43.7M) | (53.2M) | (52.1M) | (46.9M) | (49.3M) | |
| Net Income From Continuing Ops | (44.8M) | (44.2M) | (53.0M) | (50.7M) | (45.7M) | (47.9M) | |
| Ebit | (45.0M) | (43.7M) | (52.3M) | (49.5M) | (44.5M) | (46.8M) | |
| Research Development | 33.5M | 41.3M | 38.6M | 40.8M | 46.9M | 28.9M | |
| Ebitda | (44.0M) | (45.5M) | (50.5M) | (46.1M) | (41.4M) | (43.5M) | |
| Cost Of Revenue | 33.5M | (1.8M) | 1.8M | 38.1M | 43.8M | 46.0M | |
| Total Operating Expenses | 48.2M | 58.7M | 54.7M | 19.5M | 22.5M | 35.9M | |
| Income Before Tax | (44.6M) | (43.7M) | (53.0M) | (50.7M) | (45.7M) | (47.9M) | |
| Total Other Income Expense Net | 463.9K | 45.9K | 215K | 1.4M | 1.6M | 1.7M | |
| Net Income Applicable To Common Shares | (36.7M) | (44.8M) | (44.2M) | (53.0M) | (47.7M) | (50.1M) | |
| Net Income | (44.8M) | (44.2M) | (52.8M) | (50.7M) | (45.7M) | (47.9M) | |
| Income Tax Expense | 206.3K | 495K | (214.4K) | 3.3M | 3.8M | 3.9M | |
| Net Interest Income | 463.9K | 45.9K | 214.4K | 1.4M | 1.6M | 1.7M | |
| Interest Income | 463.9K | 45.9K | 928.2K | 2.7M | 3.1M | 3.2M | |
| Reconciled Depreciation | 1.1M | (1.8M) | 1.8M | 3.4M | 4.0M | 4.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| NVDA | NVIDIA | |
| CRESY | Cresud SACIF y | |
| GOOG | Alphabet Inc Class C |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 0.923 | Return On Assets | Return On Equity |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.